Journal
MOLECULAR IMAGING
Volume 16, Issue -, Pages -Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1536012117718459
Keywords
immunotherapy; PET; SPECT; optical imaging; atezolizumab; peptide; PD-1
Funding
- Allegheny Health Network-Johns Hopkins Cancer Research Fund
- NIHP30 CA006973
- [NIHR01CA16631]
Ask authors/readers for more resources
Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in, we provide an overview of our efforts to develop clinically translatable PD-L1-specific imaging agents for quantitative and real-time assessment of PD-L1 expression in tumor microenvironment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available